Portfolio News
Sofinnova MD Start
ELSAN partners with Sofinnova MD Start III, an acceleration fund dedicated to healthcare innovation and medical devices
This collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
Related Strategy
MD StartRelated Deal lead
Anne OsdoitThis collaboration aims to enable ELSAN physicians to transform their ideas for innovation into clinically-validated devices and to contribute their expertise to new projects.
June 25, 2020 - PARIS, France -
ELSAN, a leader in the private hospital sector in France, announces a strategic partnership with the Sofinnova MD START III acceleration fund. Through this partnership, ELSAN becomes an investor in the acceleration fund co-created and managed by Sofinnova Partners, a leading European venture capital firm, and offers its healthcare practitioners the means to accelerate the development of their medical device innovations for the benefit of patients.
"We are delighted that ELSAN is joining Sofinnova MD Start III as a community of clinical investigators and experts," commented Anne Osdoit, Partner at Sofinnova Partners.
Related News
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
World First: CorWave's Undulating Membrane Heart Pump Implanted in First Patient
Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in atraumatic sutureless peripheral nerve repair